How Anti‑VEGF Therapy Works to Treat Wet AMD
Wet age-related macular degeneration (wet AMD) is a leading cause of vision loss among older adults and is driven by abnormal blood vessel growth under the macula. Anti-VEGF treatment for wet AMD targets vascular endothelial growth factor (VEGF), a signaling protein that stimulates that harmful neovascularization and leakage. Since the advent of anti-VEGF therapy, many patients who would previously have experienced rapid and irreversible central vision loss can now maintain or even regain meaningful vision. Understanding how these therapies work, what to expect from treatment, and how they compare helps patients and caregivers make informed decisions with their eye care team. This article explains the mechanisms, commonly used drugs, practical considerations for treatment regimens and monitoring, and the real-world outcomes patients can reasonably expect.
What is VEGF and why blocking it matters?
VEGF is a growth factor that promotes blood vessel formation and increases vascular permeability. In wet AMD, elevated local VEGF levels encourage the growth of fragile new vessels beneath the macula that leak fluid and blood, disrupting the photoreceptors responsible for central vision. Anti-VEGF therapies are administered as intravitreal injections, delivering the drug directly into the eye to limit systemic exposure while concentrating the effect where it is needed. By neutralizing VEGF or blocking its receptor interactions, these agents reduce leakage and neovascular activity, often promoting drying of the retina and stabilizing vision. This mechanism underpins modern treatment regimens and explains why timely, repeated anti-VEGF injections are central to controlling disease activity.
How do the main anti-VEGF drugs compare?
Several anti-VEGF agents are used to treat wet AMD; they differ in molecular structure, dosing frequency, cost, and regulatory approval. Commonly used options include ranibizumab and aflibercept (approved specifically for ocular use), bevacizumab (used off-label), and newer agents with altered binding properties. Choice of drug is influenced by clinical circumstances, previous response, cost considerations, and physician experience. Below is a concise comparison to help patients understand differences commonly discussed in clinic.
| Drug | Typical ocular dose | Usual dosing interval | Mechanism | Approval context |
|---|---|---|---|---|
| Ranibizumab (e.g., Lucentis) | 0.5 mg intravitreal | Monthly or treat-and-extend | Antibody fragment that neutralizes VEGF-A | Approved for wet AMD |
| Aflibercept (e.g., Eylea) | 2.0 mg intravitreal | Often 8-weekly after loading doses; treat-and-extend used | VEGF trap binding VEGF-A, VEGF-B and PlGF | Approved for wet AMD |
| Bevacizumab (e.g., Avastin) | 1.25 mg intravitreal (off-label) | Often monthly; many clinics use treat-and-extend | Full-length anti-VEGF antibody | Off-label ocular use; commonly used for cost reasons |
| Brolucizumab | 6 mg intravitreal | Variable; 8–12 weeks for some patients | Small single-chain antibody fragment with high tissue penetration | Approved but monitored for rare inflammatory risks |
What happens during treatment and how is progress monitored?
An anti-VEGF injection is a quick outpatient procedure: the eye is numbed, disinfected, and the medication is injected into the vitreous cavity. Patients typically receive a series of monthly injections initially (loading phase) followed by one of several maintenance strategies: fixed interval dosing, pro re nata (PRN) when disease activity recurs, or treat-and-extend to lengthen intervals in stable eyes. Ongoing monitoring involves visual acuity checks and optical coherence tomography (OCT) imaging to detect retinal fluid. Commonly discussed concerns include the risk of injection-related infection (endophthalmitis), transient intraocular pressure spikes, and rare systemic vascular events; these risks are small but are discussed with each patient before treatment. Regular monitoring after anti-VEGF therapy is essential to preserve gains in vision.
Why might some patients respond less well, and what are the options?
Some patients show limited response or recurrent fluid despite treatment; reasons include chronic disease with permanent tissue damage, tachyphylaxis (reduced response to one agent), misdiagnosis, or other ocular comorbidities. When activity persists, clinicians may switch to a different anti-VEGF drug, adjust dosing frequency, or consider adjunct therapies within clinical guidelines. Research continues into biomarkers of response, combination approaches, and longer-acting formulations to reduce treatment burden. Discussions about resistance to anti-VEGF therapy and long-term outcomes are important because they set realistic expectations: many patients maintain or improve vision with sustained therapy, but continuous follow-up is often required to preserve benefits.
Cost, access and practical steps patients can take
Cost and access are practical realities. Bevacizumab is generally less expensive when repackaged for ocular use, which makes it an important option in many health systems, while ranibizumab and aflibercept are typically more costly but are approved specifically for the eye. Insurance coverage, regional formularies, and clinic protocols influence choice. Patients are encouraged to learn about home monitoring tools — from the simple Amsler grid to validated smartphone-based monitoring — so changes in central vision are reported promptly. Discuss with your ophthalmologist or retina specialist which treatment regimen and monitoring plan best fits clinical needs, lifestyle, and financial considerations.
Balancing benefits and risks — what matters most
Anti-VEGF therapy transformed management of wet AMD by targeting the biological driver of vision loss, and most treated patients can expect stabilization or improvement if therapy is started early and maintained as recommended. The decision about which agent to use, how often to inject, and when to switch is individualized and made in partnership with a retina specialist. This article provides an overview of mechanisms, common agents, expected monitoring, and practical considerations but does not replace a personalized medical consultation. For specific medical advice, diagnosis, or treatment decisions, consult a qualified eye care professional who can evaluate your individual condition and discuss the risks, benefits, and alternatives.
This text was generated using a large language model, and select text has been reviewed and moderated for purposes such as readability.
